目的探讨枳术宽中胶囊联合莫沙必利对2型糖尿病胃轻瘫患者的疗效及其对胃肠激素水平的影响。方法选取三亚市人民医院2019年4月-2020年5月收治的128例2型糖尿病胃轻瘫患者，按照治疗方法将患者分为对照组和观察组，每组64例。对照组患者餐前口服枸橼酸莫沙必利片，5 mg/次，3次/d。观察组在对照组基础上加用枳术宽中胶囊，3粒/次，3次/d。两组疗程均为4周。观察两组患者的临床疗效，同时比较两组治疗前后的胃轻瘫症状指数（GCSI）、半胃排空时间，以及胃泌素（GAS）和胃动素（MOT）的水平变化。结果治疗后，观察组总有效率为90.6%，显著高于对照组的76.6%（P<0.05）。治疗后，两组GCSI评分和半胃排空时间均显著减低（P<0.05），且观察组GCSI评分和半胃排空时间显著低于对照组（P<0.05）。治疗后，两组GAS和MOT水平均显著减低（P<0.05）；观察组GAS和MOT显著低于对照组（P<0.05）。结论枳术宽中胶囊联合莫沙必利可以显著抑制糖尿病胃轻瘫患者GAS和MOT水平，增强胃动力，临床疗效显著，使用安全。

Objective To investigate the effect of Zhizhu Kuanzhong Capsules combined with mosapride on type 2 diabetic gastroparesis and its effect on gastrointestinal hormone levels. Methods A total of 128 patients with type 2 diabetic gastroparesis admitted to Sanya People's Hospital from April 2019 to May 2020 were selected. According to the treatment methods, the 128 patients were divided into control group and observation group, with 64 patients in each group. Patients in the control group were po administered with Mosapride Citrate Tablets before meal, 5 mg/time, three times daily. Patients in the observation group were po administered with Zhizhu Kuanzhong Capsules on the basis of control group, 3 grains/time, three times daily. The treatment course of both groups was 4 weeks. The clinical efficacy of two groups was observed, and the changes of gastroparesis symptom index (GCSI), GAS and MOT levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of observation group was 90.6%, which was significantly higher than 76.6% of control group (P < 0.05). After treatment, GCSI score and hemigastric emptying time in two groups were significantly decreased (P < 0.05), and GCSI score and hemigastric emptying time in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of GAS and MOT in two groups were significantly decreased (P < 0.05). And the levels of GAS and MOT in observation group were significantly lower than those in control group (P < 0.05). Conclusion Zhizhu Kuanzhong Capsules combined with mosapride can significantly inhibit the levels of GAS and MOT in patients with diabetic gastroparesis, enhance gastric motility, with significant clinical efficacy and safe use.

R975

海南省卫生计生行业科研项目（16A200069）